[{"address1": "611 Gateway Boulevard", "address2": "Suite 120", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 484 0886", "website": "https://graphitebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction. Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.", "fullTimeEmployees": 6, "auditRisk": 8, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1709251200, "maxAge": 86400, "priceHint": 4, "previousClose": 3.27, "open": 3.2, "dayLow": 3.05, "dayHigh": 3.2316, "regularMarketPreviousClose": 3.27, "regularMarketOpen": 3.2, "regularMarketDayLow": 3.05, "regularMarketDayHigh": 3.2316, "exDividendDate": 1711065600, "beta": 0.196, "forwardPE": -7.9500003, "volume": 299406, "regularMarketVolume": 299406, "averageVolume": 270040, "averageVolume10days": 501900, "averageDailyVolume10Day": 501900, "bid": 3.14, "ask": 3.23, "bidSize": 100, "askSize": 700, "marketCap": 185193344, "fiftyTwoWeekLow": 2.01, "fiftyTwoWeekHigh": 18.195, "fiftyDayAverage": 3.8484, "twoHundredDayAverage": 2.81825, "currency": "USD", "enterpriseValue": 1296411, "floatShares": 2382638, "sharesOutstanding": 58236900, "sharesShort": 100577, "sharesShortPriorMonth": 114539, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0017, "shortRatio": 7.93, "shortPercentOfFloat": 0.0028, "impliedSharesOutstanding": 58236900, "bookValue": 22.153, "priceToBook": 0.14354715, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -124651000, "trailingEps": -15.33, "forwardEps": -0.4, "pegRatio": -0.31, "lastSplitFactor": "1:7", "lastSplitDate": 1711065600, "enterpriseToEbitda": -0.018, "52WeekChange": 5.888889, "SandP52WeekChange": 0.29191303, "lastDividendValue": 1.03, "lastDividendDate": 1711065600, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "GRPH", "underlyingSymbol": "GRPH", "shortName": "Graphite Bio, Inc.", "longName": "Graphite Bio, Inc.", "firstTradeDateEpochUtc": 1624627800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0e2cca8f-1aec-3e6d-80d3-39814500dbb7", "messageBoardId": "finmb_688617627", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.18, "targetHighPrice": 7.0, "targetLowPrice": 7.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 184259008, "totalCashPerShare": 22.148, "ebitda": -71041000, "totalDebt": 362000, "quickRatio": 38.411, "currentRatio": 39.196, "debtToEquity": 0.197, "returnOnAssets": -0.17989, "returnOnEquity": -0.51952, "freeCashflow": -44892000, "operatingCashflow": -90007000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-27"}]